Recently, the research team led by Wei Li and Chao Liu from Guangzhou Medical University Affiliated Women and Children's Medical Center, in ...

Acrivon Therapeutics, Inc.’s ACRV share price has dipped by 11.25%, which has investors questioning if this is right time to ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

I place far more faith on the phenomenal amount of work she has carried out on CHK 1 inhibitors which include 737 and Prexasertib ( Prexasertib is a Chk1/2 inhibitor. Resistance to CHK1 can be ...

Zach Hornby: Our first clinical programme, BBI355, is an oral CHK1 inhibitor. We should read out data from our Phase 1b component by the end of this year. We're looking for preliminary proof of ...

Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days ...

Metagenomic and targeted metabolomic analyses reveal distinct phenotypes of the gut microbiota in patients with colorectal cancer and type 2 diabetes mellitus.